SlateStone Wealth LLC Has $2.12 Million Stock Position in SPDR S&P Biotech ETF (NYSEARCA:XBI)

SlateStone Wealth LLC lowered its position in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI) by 2.0% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 22,286 shares of the exchange traded fund’s stock after selling 450 shares during the quarter. SlateStone Wealth LLC’s holdings in SPDR S&P Biotech ETF were worth $2,120,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in XBI. FMR LLC increased its position in shares of SPDR S&P Biotech ETF by 57.3% during the 1st quarter. FMR LLC now owns 55,876 shares of the exchange traded fund’s stock worth $5,059,000 after purchasing an additional 20,363 shares in the last quarter. Parametric Portfolio Associates LLC acquired a new stake in SPDR S&P Biotech ETF in the 2nd quarter valued at about $223,000. Howard Capital Management increased its position in SPDR S&P Biotech ETF by 5.8% in the 3rd quarter. Howard Capital Management now owns 144,840 shares of the exchange traded fund’s stock valued at $11,044,000 after acquiring an additional 7,900 shares in the last quarter. Pettinga Financial Advisors LLC increased its position in SPDR S&P Biotech ETF by 290.8% in the 3rd quarter. Pettinga Financial Advisors LLC now owns 13,875 shares of the exchange traded fund’s stock valued at $1,058,000 after acquiring an additional 10,325 shares in the last quarter. Finally, Hanson & Doremus Investment Management increased its position in SPDR S&P Biotech ETF by 3,279.1% in the 3rd quarter. Hanson & Doremus Investment Management now owns 4,359 shares of the exchange traded fund’s stock valued at $332,000 after acquiring an additional 4,230 shares in the last quarter.

XBI traded up $0.17 during midday trading on Friday, hitting $97.09. The company had a trading volume of 2,051,728 shares, compared to its average volume of 4,943,314. SPDR S&P Biotech ETF has a twelve month low of $72.97 and a twelve month high of $98.79. The firm’s 50-day simple moving average is $94.30 and its 200-day simple moving average is $86.79.

About SPDR S&P Biotech ETF

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

Recommended Story: Closed-End Mutual Funds

Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI).

Institutional Ownership by Quarter for SPDR S&P Biotech ETF (NYSEARCA:XBI)

Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.